Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  GenSight Biologics S.A.    SIGHT   FR0013183985

GENSIGHT BIOLOGICS S.A.

(SIGHT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
GenSight Biologics S.A. specializes in the research and development of gene therapies for the treatment of mitochondrial diseases and eye neurodegeneratives.

At the end of 2019, the company had a portfolio of 2 products, including 1 in phase III clinical development (GS010 for the treatment of Leber's hereditary optic neuropathy) and 1 in phase I/II clinical development (GS030 for the treatment of retinitis pigmentosa).

Number of employees : 25 people.
Sales per Business
20182019Delta
EUR (in Million)%EUR (in Million)%
Novel Therapies for Mitochondrial and Neurodegenerative Disease--0.700100%-
Sales per region
20182019Delta
EUR (in Million)%EUR (in Million)%
France--0.700100%-
Managers
NameAgeSinceTitle
Bernard Jacques Alex Gilly, Dr.622016Chief Executive Officer & Director
Michael S. Wyzga642016Chairman
Thomas Gidoin362015Chief Financial Officer
Magali Taiel, Dr.-2019Chief Medical Officer
José-Alain Sahel, Dr.65-Director
Peter Goodfellow, Dr.672014Independent Director
Simone Seiter, Dr.-2017Independent Director
Natalie Marianne Mount, Dr.-2017Independent Director
Thibaut Roulon, Dr.--Director
Maritza C. McIntyre, Dr.-2019Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 32,827,362 31,326,928 95.4% 0 0.0% 95.4%
Shareholders
NameEquities%
Sofinnova Partners SAS 5,610,044 14.1%
Bpifrance Participations SA /PRIVATE EQUITY/ 2,000,000 5.04%
Versant Venture Management LLC 1,576,428 3.97%
Abingworth LLP 1,402,588 3.53%
Novartis AG 1,390,487 3.50%
Vitavest S.à.r.l. 1,339,706 3.38%
BPIFrance Investissement SAS 975,666 2.46%
Sycomore Asset Management SA 497,859 1.25%
APG Asset Management NV 270,270 0.68%
Fidelity Management & Research Co. LLC 233,574 0.59%
Markets and indexes
- PEA / SRD eligible : YES / YES
-
- Compartiment C
- CAC Small / CAC All Shares, CAC All-Tradable, CAC Mid Small, CAC PME, EnterNext© PEA-PME 150, Next Biotech, PEA, PEA-PME
Stock Exchange Codes
- Bloomberg Code :  SIGHT:FR
- Reuters Code :  SIGHT.PA
- Datastream Code :  
Company contact information
GenSight Biologics S.A.
74 Rue du Faubourg Saint-Antoine
FR-75012 Paris


Phone : +33 (0)1 76 21 72 20
Fax :
web site : http://www.gensight-biologics.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of GenSight Biologics S.A.
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
GENSIGHT BIOLOGICS S.A.124.95%263
GILEAD SCIENCES, INC.-7.28%75 525
VERTEX PHARMACEUTICALS-1.12%56 298
REGENERON PHARMACEUTICALS34.79%53 416
WUXI APPTEC CO., LTD.59.64%38 761
BIONTECH SE200.68%24 529
BEIGENE, LTD.54.55%23 352
GENMAB A/S49.17%23 080
ARGENX SE52.37%12 308
MYOKARDIA, INC.208.58%11 993
HUALAN BIOLOGICAL ENGINEERING INC.56.55%11 716
MIRATI THERAPEUTICS, INC.72.99%11 233
SAREPTA THERAPEUTICS, INC.4.70%10 662
NEUROCRINE BIOSCIENCES, INC.-12.90%8 951
ASCENDIS PHARMA A/S14.49%8 508
ULTRAGENYX PHARMACEUTICAL INC.178.34%7 865
DENALI THERAPEUTICS INC.250.29%7 317
BIOCON LIMITED47.62%6 941
ACCELERON PHARMA INC.115.18%6 874
ARROWHEAD PHARMACEUTICALS, INC.-4.79%6 183
KODIAK SCIENCES INC.69.56%6 150